about
Serum concentrations of cefotaxime and its metabolite desacetyl-cefotaxime in infants and children during continuous infusionResistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypesConsumption of antimicrobials in pigs, veal calves, and broilers in the Netherlands: quantitative results of nationwide collection of data in 2011.A structural comparison of lipopolysaccharide biosynthesis loci of Legionella pneumophila serogroup 1 strains.Chlamydia antibody testing and diagnosing tubal pathology in subfertile women: an individual patient data meta-analysis.Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates.Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosisEUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density.Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates.A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazolePosaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh modelPharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelWhich cephalosporin for gonorrhoea?Impact of pharmacodynamics on breakpoint selection for susceptibility testing.Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population.New dosing strategies for antibacterial agents in the neonate.Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemiaPharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serumPharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosisContinuous infusion of beta-lactams.Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women.Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?Different demographic and sexual correlates for chlamydial infection and gonorrhoea in Rotterdam.Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR.Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia.Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Assessment of bactericidal drug activity and treatment outcome in a mouse tuberculosis model using a clinical Beijing strain.Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.A role for TLR1, TLR2 and NOD2 in cytokine induction by Bacteroides fragilis.
P50
Q28293879-C3C20264-502C-41BA-8004-872997ED64F5Q28731332-F5C90E86-C715-405D-B53D-42033A486210Q30690839-37BBB9AA-CA55-482C-8E5D-4E2100309EFFQ31140251-F36956B3-B623-4875-ACD4-7A8F8806B77BQ33791615-0731FE4C-C628-41A6-9308-037E8B2D95F1Q34041500-B981D1EE-C42D-4DF5-9FB2-21BECF4DA551Q34109399-257AAD42-9319-4B98-B615-C6B4F6D7E1B8Q34596993-3BDCE002-61A0-481C-8BB1-00A57DB10F49Q34977071-5CD86F5E-5469-443D-BC79-C1BB440892D1Q34993851-5ECB32F2-1B8A-4D0A-A5F9-2644F543EB0AQ35065903-B2B1A350-E502-45BB-AF81-563D795BC071Q35076830-4294A6BE-9737-4C06-9233-D89E647CA7DEQ35076940-0EFDEBDA-DBCD-48E0-94F2-CB42926C4ECEQ35106016-A4044DCD-97E5-4C03-8959-D42E645F0E73Q35168955-3543D1E5-E485-490D-9DDF-35088EC2E235Q35385554-18775D62-DDEC-46D5-BC0B-B15BF4CEB92DQ35531502-BDB9924B-3387-48F2-8788-60F93C69988FQ35623076-73DA6DDB-26BD-40C1-A485-BB0BEFE59DF4Q36022995-13CE9D55-A8BA-4B87-A9FD-3476C122E17DQ36035169-2278C9A0-B059-4483-A9C4-23A2B1CC24CAQ36094974-8BED88DC-CE46-4DFA-9C90-4DB5C3898859Q36439179-4573D30F-4E20-448E-A4B0-2B4C1E30A4DFQ36505281-2AB5C0FF-AE84-4BB3-A037-06843F48134EQ36558484-0EA69361-C3FC-4244-A9ED-02DADC11CF9CQ36571794-3ACDF217-A0BF-49EA-BB88-2AE380A4CE3EQ36757617-592F5AB6-E5C4-4E83-9382-820D9428D013Q36757621-70FDFE99-FD9B-47C2-99B0-82E67E629F05Q36924963-F7E25672-4F9A-4F89-A28F-779D972D1B52Q36933441-D0522850-F62F-40C3-BA26-5B3A5C280A20Q37175822-ADBF342C-1DBD-436B-BFB8-4592A7899208Q37428654-EB2CB0B6-CEA1-40B1-B54C-B43083DBBE06Q37778640-5694CCED-5D22-46D3-B0FF-B6E7D5BFCE9CQ37881691-82A9A9FF-1B26-443E-B45B-87EFEC8F3D05Q37926156-4C50B0A2-19AD-440A-99FB-CAD40D2C5CF3Q37971365-3705FE78-F15C-4AA8-A0EC-D2C552025941Q38004711-36A328B5-8A6D-4CB8-A522-CD421BCBDA2EQ38140015-A3B7A50E-D498-4D96-912E-DADCBCAE4B84Q38652464-6C611177-EEC1-46E8-A287-B81DA5520BCCQ38718394-C8BCF281-9A2C-4AA0-8D1B-5CC484B10362Q39274271-87ED4057-21D6-453C-AFB5-A307C52D8A34
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Johan Mouton
@ast
Johan Mouton
@en
Johan Mouton
@es
Johan Mouton
@nl
Johan Mouton
@sl
type
label
Johan Mouton
@ast
Johan Mouton
@en
Johan Mouton
@es
Johan Mouton
@nl
Johan Mouton
@sl
prefLabel
Johan Mouton
@ast
Johan Mouton
@en
Johan Mouton
@es
Johan Mouton
@nl
Johan Mouton
@sl
P1053
C-5915-2014
P106
P21
P31
P3829
P496
0000-0001-6736-4149